Artia Global Partners L.P. 13F annual report
Artia Global Partners L.P. is an investment fund managing more than $390 billion ran by Onusa Chantanapongwanij. There are currently 42 companies in Chantanapongwanij’s portfolio. The largest investments include Novo-nordisk A S and Eli Lilly Co, together worth $183 billion.
$390 billion Assets Under Management (AUM)
As of 7th August 2024, Artia Global Partners L.P.’s top holding is 691,743 shares of Novo-nordisk A S currently worth over $98.7 billion and making up 25.3% of the portfolio value.
In addition, the fund holds 92,593 shares of Eli Lilly Co worth $83.8 billion.
The third-largest holding is Merck Co Inc worth $54.8 billion and the next is Viking Therapeutics Inc worth $24 billion, with 452,979 shares owned.
Currently, Artia Global Partners L.P.'s portfolio is worth at least $390 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Artia Global Partners L.P.
The Artia Global Partners L.P. office and employees reside in Miami, Florida. According to the last 13-F report filed with the SEC, Onusa Chantanapongwanij serves as the Managing Partner at Artia Global Partners L.P..
Recent trades
In the most recent 13F filing, Artia Global Partners L.P. revealed that it had opened a new position in
Alnylam Pharmaceuticals Inc and bought 35,000 shares worth $8.51 billion.
This means they effectively own approximately 0.1% of the company.
Alnylam Pharmaceuticals Inc makes up
6.3%
of the fund's Health Care sector allocation and has grown its share price by 47.6% in the past year.
The investment fund also strengthened its position in Merck Co Inc by buying
63,304 additional shares.
This makes their stake in Merck Co Inc total 442,504 shares worth $54.8 billion.
On the other hand, there are companies that Artia Global Partners L.P. is getting rid of from its portfolio.
Artia Global Partners L.P. closed its position in Abbvie Inc on 14th August 2024.
It sold the previously owned 90,821 shares for $16.5 billion.
Onusa Chantanapongwanij also disclosed a decreased stake in Vertex Pharmaceuticals by 0.3%.
This leaves the value of the investment at $8.86 billion and 18,900 shares.
One of the smaller hedge funds
The two most similar investment funds to Artia Global Partners L.P. are Martin Investment Management and Kensington Investments B.v. They manage $390 billion and $390 billion respectively.
Onusa Chantanapongwanij investment strategy
Artia Global Partners L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 34.7% of
the total portfolio value.
The fund focuses on investments in the United States as
57.1% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
12% of the total holdings value.
On the other hand, small-cap stocks make up only 9.5% of the portfolio.
The average market cap of the portfolio companies is close to $12.5 billion.
The complete list of Artia Global Partners L.P. trades based on 13F SEC filings
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Novo-nordisk A S |
No change
691,743
|
$98,739,396,000 | 25.33% |
| Eli Lilly Co |
No change
92,593
|
$83,831,850,000 | 21.50% |
| Merck Co Inc |
16.69%
442,504
|
$54,781,995,000 | 14.05% |
| Viking Therapeutics Inc |
4.47%
452,979
|
$24,012,417,000 | 6.16% |
| Abbvie Inc |
Closed
90,821
|
$16,538,504,000 | |
| Astrazeneca plc |
No change
190,752
|
$14,876,748,000 | 3.82% |
| Intra-Cellular Therapies Inc |
3.06%
216,519
|
$14,829,386,000 | 3.80% |
| Vertex Pharmaceuticals, Inc. |
34.60%
18,900
|
$8,858,808,000 | 2.27% |
| Alnylam Pharmaceuticals Inc |
Opened
35,000
|
$8,505,000,000 | 2.18% |
| Axsome Therapeutics Inc |
No change
87,848
|
$7,071,764,000 | 1.81% |
| Argenx Se |
55.79%
15,138
|
$6,509,946,000 | 1.67% |
| Cytokinetics Inc |
Closed
89,525
|
$6,276,598,000 | |
| Neurocrine Biosciences, Inc. |
No change
45,000
|
$6,195,150,000 | 1.59% |
| Vaxcyte, Inc. |
No change
76,255
|
$5,758,015,000 | 1.48% |
| Protagonist Therapeutics Inc |
No change
124,440
|
$4,311,846,000 | 1.11% |
| Dyne Therapeutics, Inc. |
No change
119,488
|
$4,216,732,000 | 1.08% |
| Soleno Therapeutics Inc |
130.73%
94,424
|
$3,852,499,000 | 0.99% |
| Crinetics Pharmaceuticals In |
No change
85,765
|
$3,841,414,000 | 0.99% |
| Insmed Inc |
54.81%
53,436
|
$3,580,212,000 | 0.92% |
| Ocular Therapeutix Inc |
31.00%
500,000
|
$3,420,000,000 | 0.88% |
| Ionis Pharmaceuticals Inc |
Opened
62,479
|
$2,977,749,000 | 0.76% |
| Merus N.V |
No change
50,171
|
$2,968,618,000 | 0.76% |
| Celldex Therapeutics Inc. |
Opened
75,300
|
$2,786,853,000 | 0.71% |
| Apogee Therapeutics Inc |
5.18%
58,400
|
$2,298,040,000 | 0.59% |
| Alpine Immune Sciences Inc |
Closed
51,714
|
$2,049,943,000 | |
| SpringWorks Therapeutics, Inc. |
No change
53,930
|
$2,031,543,000 | 0.52% |
| IDEAYA Biosciences, Inc. |
3.62%
54,392
|
$1,909,703,000 | 0.49% |
| Verona Pharma Plc |
No change
130,790
|
$1,891,223,000 | 0.49% |
| Janux Therapeutics Inc |
Closed
47,949
|
$1,805,280,000 | |
| Arvinas Inc |
Closed
40,000
|
$1,651,200,000 | |
| Xenon Pharmaceuticals Inc |
No change
40,000
|
$1,559,600,000 | 0.40% |
| Mereo BioPharma Group plc |
No change
421,359
|
$1,516,892,000 | 0.39% |
| Charles Riv Labs Intl Inc |
No change
6,905
|
$1,426,435,000 | 0.37% |
| RAPT Therapeutics, Inc. |
Closed
137,308
|
$1,233,026,000 | |
| Kura Oncology Inc |
44.84%
57,178
|
$1,177,295,000 | 0.30% |
| Vera Therapeutics Inc |
Closed
24,298
|
$1,047,730,000 | |
| Newamsterdam Pharma Company |
No change
54,285
|
$1,042,815,000 | 0.27% |
| Ascendis Pharma A/S |
53.19%
7,440
|
$1,014,667,000 | 0.26% |
| Silence Therapeutics plc |
No change
52,476
|
$997,044,000 | 0.26% |
| Syndax Pharmaceuticals Inc |
Opened
48,263
|
$990,839,000 | 0.25% |
| Macrogenics Inc |
Closed
64,007
|
$942,183,000 | |
| Keros Therapeutics, Inc. |
Opened
20,000
|
$914,000,000 | 0.23% |
| Corbus Pharmaceuticals Hldgs |
Opened
20,000
|
$905,000,000 | 0.23% |
| EyePoint Pharmaceuticals Inc |
97.09%
101,500
|
$883,050,000 | 0.23% |
| Annexon Inc |
No change
147,485
|
$722,677,000 | 0.19% |
| Immunovant Inc |
Closed
21,397
|
$691,337,000 | |
| Larimar Therapeutics, Inc. |
55.51%
90,490
|
$656,053,000 | 0.17% |
| Disc Medicine Inc |
84.56%
13,440
|
$605,741,000 | 0.16% |
| Pliant Therapeutics, Inc. |
50.00%
50,000
|
$537,500,000 | 0.14% |
| Biomea Fusion Inc |
Closed
35,452
|
$530,007,000 | |
| Madrigal Pharmaceuticals Inc |
No change
1,557
|
$436,209,000 | 0.11% |
| Sarepta Therapeutics Inc |
Opened
2,600
|
$410,800,000 | 0.11% |
| Poseida Therapeutics, Inc. |
Closed
86,002
|
$274,346,000 | |
| Gritstone Bio Inc |
Closed
95,170
|
$244,587,000 | |
| No transactions found | |||
| Showing first 500 out of 54 holdings | |||
Hedge funds similar to Artia Global Partners L.P.
- B.o.s.s. Retirement Advisors
- Traverso Chambers Private Wealth Management
- Pettinga Advisors
- Minichmacgregor Wealth Management
- Bwcp, L.P.
- Oak Grove Capital
- Old Second National Bank Of Aurora
- Martin Investment Management
- Kensington Investments B.v
- Stony Point Capital
- Mitchell Sinkler & Starr/pa
- Harbor
- First Pacific
- Optas